Please login to the form below

Not currently logged in
Email:
Password:

Takeda to take over Tianjin Takeda

Takeda Pharmaceutical has announced it is to obtain full ownership of Tianjin Takeda, expanding the company's role in China

Japanese company, Takeda Pharmaceutical, has announced it is to obtain full ownership of Tianjin Takeda - a China-based joint venture between Takeda and Tianjin Lisheng Pharmaceutical established in 1994.

The deal will see Takeda, which currently holds 75 per cent of Tianjin Takeda, acquire the 25 per cent share of the company held by Tianjin Lisheng.

Financial details of the deal were not disclosed.

Speaking on the deal, Haruhiko Hirate, corporate officer, senior vice president, international operations (Asia) of Takeda, said: "It is an important milestone event for Takeda to obtain the full ownership of Tianjin Takeda as we are aiming to rapidly expand our business in China that is already fifth largest pharmaceutical market in the world with one of the fastest growing trend."

He continued: "We will establish and implement further proactive and flexible sales and marketing strategies for existing products, while proceeding to earliest possible registration and launch of new products ... so that we can enhance Takeda's presence in China as early as possible."

The board of directors at Tianjin Lisheng announced its decision to sell its share of the joint venture in August 2010.

As a state-owned company, Tianjin Lisheng's holdings were put up for public bidding, with applications taken from September 9, 2010 to October 13, 2010.

By the end of the application period, Takeda was sole bidder for the equity held by Tianjin Lisheng, allowing the Takeda's complete takeover of the venture.

19th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics